Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vitae Pharmaceuticals has appointed Christine Brennan as a new chief business officer. Earlier, she served as an executive director and head of strategy and operations for strategic alliances at Novartis’ Institutes for BioMedical Research.
Subscribe to our email newsletter
Prior to Novartis, Dr Brennan worked at Fidelity Biosciences and prior to that worked in business development for several early-stage biotechnology companies.
Jeffrey Hatfield, CEO of Vitae Pharmaceuticals, said: “The life sciences industry is tracking on a path of tremendous change, centered around a rapidly increasing link – even co-dependency – between large pharma and biotech.
“With Vitae’s multiple clinical programs, expanding pipeline and highly productive and capital efficient discovery engine, making Vitae a more outward-facing organisation became the next critical step in our evolution. I am especially pleased to gain the help of someone as talented and successful as Christine for this important role.”
Dr Brennan said: “I am delighted to be a part of the successful team at Vitae and I look forward to helping the company and its partners – both current and future – achieve their goals together via strategically aligned and value accelerating collaborations.”